Curaxis Pharmaceutical (Curaxis Pharmaceutical) EV-to-EBIT : -0.04 (As of May. 05, 2024)

View and export this data going back to . Start your Free Trial

What is Curaxis Pharmaceutical EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Curaxis Pharmaceutical's Enterprise Value is $0.07 Mil. Curaxis Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Dec. 2011 was $-1.92 Mil. Therefore, Curaxis Pharmaceutical's EV-to-EBIT for today is -0.04.

The historical rank and industry rank for Curaxis Pharmaceutical's EV-to-EBIT or its related term are showing as below:

CURXQ's EV-to-EBIT is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 17.86
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Curaxis Pharmaceutical's Enterprise Value for the quarter that ended in Dec. 2011 was $6.96 Mil. Curaxis Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Dec. 2011 was $-1.92 Mil. Curaxis Pharmaceutical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2011 was -27.61%.

Curaxis Pharmaceutical EV-to-EBIT Historical Data

The historical data trend for Curaxis Pharmaceutical's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curaxis Pharmaceutical EV-to-EBIT Chart

Curaxis Pharmaceutical Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

EV-to-EBIT

-22.45

-3.62

Curaxis Pharmaceutical Semi-Annual Data
	Dec08	Dec09	Dec10	Dec11
EV-to-EBIT	-	-	-	-

Competitive Comparison of Curaxis Pharmaceutical's EV-to-EBIT

For the Drug Manufacturers - General subindustry, Curaxis Pharmaceutical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curaxis Pharmaceutical's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Curaxis Pharmaceutical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Curaxis Pharmaceutical's EV-to-EBIT falls into.

Curaxis Pharmaceutical EV-to-EBIT Calculation

Curaxis Pharmaceutical's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	0.070	/	-1.922
	=	-0.04

Curaxis Pharmaceutical's current Enterprise Value is $0.07 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Curaxis Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Dec. 2011 was $-1.92 Mil.

Curaxis Pharmaceutical (OTCPK:CURXQ) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Curaxis Pharmaceutical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2011 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2011 )	=	EBIT	/	Enterprise Value (Q: Dec. 2011 )
	=	-1.922	/	6.9608
	=	-27.61 %

Curaxis Pharmaceutical's Enterprise Value for the quarter that ended in Dec. 2011 was $6.96 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Curaxis Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Dec. 2011 was $-1.92 Mil.

Curaxis Pharmaceutical EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Curaxis Pharmaceutical's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Curaxis Pharmaceutical (Curaxis Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Curaxis Pharmaceutical Corp (OTCPK:CURXQ) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.curaxispharma.com

Curaxis Pharmaceutical Corp was incorporated in Delaware on February 27, 2001. It is a specialty pharmaceutical company with a hormone drug product candidate for the treatment of Alzheimer's disease. The Company's therapeutic platform is based on the hypothesis that diseases of aging may be caused by age-related changes in the function of the hypothalamic-pituitary-gonadal (HPG) axis. The HPG axis is a hormonal endocrine feedback loop that controls development, reproduction and aging in animals. This drug development platform is built on the premise that hormones associated with this feedback loop are beneficial early in life, when they promote growth and development, but are harmful later in life when the mechanism for feedback is compromised, thereby leading to disease processes, including pathologies associated with Alzheimer's disease and various cancers. Its discovery of similar hormonal signaling mechanisms at the cellular level in brain tissue from Alzheimer's patients and in multiple tumors will enable it to develop significant new treatments for Alzheimer's disease and may have applications for many cancers.

Executives

Timothy R Wright	director, officer: Chief Executive Officer	C/O CURAXIS, 1004 CHAGFORD WAY, RALEIGH NC 27614
Michael W George	director	C/O CURAXIS, 1004 CHAGFORD WAY, RALEIGH NC 27614

Curaxis Pharmaceutical (Curaxis Pharmaceutical) Headlines

No Headlines